-
Transferable Graph Neural Fingerprint Models for Quick Response to Future Bio-Threats
Authors:
Wei Chen,
Yihui Ren,
Ai Kagawa,
Matthew R. Carbone,
Samuel Yen-Chi Chen,
Xiaohui Qu,
Shinjae Yoo,
Austin Clyde,
Arvind Ramanathan,
Rick L. Stevens,
Hubertus J. J. van Dam,
Deyu Lu
Abstract:
Fast screening of drug molecules based on the ligand binding affinity is an important step in the drug discovery pipeline. Graph neural fingerprint is a promising method for develo** molecular docking surrogates with high throughput and great fidelity. In this study, we built a COVID-19 drug docking dataset of about 300,000 drug candidates on 23 coronavirus protein targets. With this dataset, we…
▽ More
Fast screening of drug molecules based on the ligand binding affinity is an important step in the drug discovery pipeline. Graph neural fingerprint is a promising method for develo** molecular docking surrogates with high throughput and great fidelity. In this study, we built a COVID-19 drug docking dataset of about 300,000 drug candidates on 23 coronavirus protein targets. With this dataset, we trained graph neural fingerprint docking models for high-throughput virtual COVID-19 drug screening. The graph neural fingerprint models yield high prediction accuracy on docking scores with the mean squared error lower than $0.21$ kcal/mol for most of the docking targets, showing significant improvement over conventional circular fingerprint methods. To make the neural fingerprints transferable for unknown targets, we also propose a transferable graph neural fingerprint method trained on multiple targets. With comparable accuracy to target-specific graph neural fingerprint models, the transferable model exhibits superb training and data efficiency. We highlight that the impact of this study extends beyond COVID-19 dataset, as our approach for fast virtual ligand screening can be easily adapted and integrated into a general machine learning-accelerated pipeline to battle future bio-threats.
△ Less
Submitted 14 September, 2023; v1 submitted 17 July, 2023;
originally announced August 2023.
-
IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads
Authors:
Aymen Al Saadi,
Dario Alfe,
Yadu Babuji,
Agastya Bhati,
Ben Blaiszik,
Thomas Brettin,
Kyle Chard,
Ryan Chard,
Peter Coveney,
Anda Trifan,
Alex Brace,
Austin Clyde,
Ian Foster,
Tom Gibbs,
Shantenu Jha,
Kristopher Keipert,
Thorsten Kurth,
Dieter Kranzlmüller,
Hyungro Lee,
Zhuozhao Li,
Heng Ma,
Andre Merzky,
Gerald Mathias,
Alexander Partin,
Junqi Yin
, et al. (11 additional authors not shown)
Abstract:
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating…
▽ More
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating the entire process. No single methodological approach can achieve the necessary accuracy with required efficiency. Here we describe multiple algorithmic innovations to overcome this fundamental limitation, development and deployment of computational infrastructure at scale integrates multiple artificial intelligence and simulation-based approaches. Three measures of performance are:(i) throughput, the number of ligands per unit time; (ii) scientific performance, the number of effective ligands sampled per unit time and (iii) peak performance, in flop/s. The capabilities outlined here have been used in production for several months as the workhorse of the computational infrastructure to support the capabilities of the US-DOE National Virtual Biotechnology Laboratory in combination with resources from the EU Centre of Excellence in Computational Biomedicine.
△ Less
Submitted 13 October, 2020;
originally announced October 2020.
-
Targeting SARS-CoV-2 with AI- and HPC-enabled Lead Generation: A First Data Release
Authors:
Yadu Babuji,
Ben Blaiszik,
Tom Brettin,
Kyle Chard,
Ryan Chard,
Austin Clyde,
Ian Foster,
Zhi Hong,
Shantenu Jha,
Zhuozhao Li,
Xuefeng Liu,
Arvind Ramanathan,
Yi Ren,
Nicholaus Saint,
Marcus Schwarting,
Rick Stevens,
Hubertus van Dam,
Rick Wagner
Abstract:
Researchers across the globe are seeking to rapidly repurpose existing drugs or discover new drugs to counter the the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One promising approach is to train machine learning (ML) and artificial intelligence (AI) tools to screen large numbers of small molecules. As a contribution to that effort,…
▽ More
Researchers across the globe are seeking to rapidly repurpose existing drugs or discover new drugs to counter the the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One promising approach is to train machine learning (ML) and artificial intelligence (AI) tools to screen large numbers of small molecules. As a contribution to that effort, we are aggregating numerous small molecules from a variety of sources, using high-performance computing (HPC) to computer diverse properties of those molecules, using the computed properties to train ML/AI models, and then using the resulting models for screening. In this first data release, we make available 23 datasets collected from community sources representing over 4.2 B molecules enriched with pre-computed: 1) molecular fingerprints to aid similarity searches, 2) 2D images of molecules to enable exploration and application of image-based deep learning methods, and 3) 2D and 3D molecular descriptors to speed development of machine learning models. This data release encompasses structural information on the 4.2 B molecules and 60 TB of pre-computed data. Future releases will expand the data to include more detailed molecular simulations, computed models, and other products.
△ Less
Submitted 27 May, 2020;
originally announced June 2020.
